StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)

Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –

BioMarin Pharmaceutical price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BioMarin Pharmaceutical's price to sales ratio was 3.3× on Nov 11, 2026, against 3.5× a year earlier. Over the last 5 years it ranged from 3.2× to 10.7×, with a median of 6.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.3×−0.4
2025Dec 31, 20253.7×−0.9
2024Dec 31, 20244.5×−3.3
2023Dec 29, 20237.9×−1.7
2022Dec 30, 20229.6×+0.8
2021Dec 31, 20218.8×+0.2
2020Dec 31, 20208.5×−0.9
2019Dec 31, 20199.5×−0.6
2018Dec 31, 201810.1×−2.3
2017Dec 29, 201712.5×−1.2
2016Dec 30, 201613.6×−5.3
2015Dec 31, 201518.9×−1.1
2014Dec 31, 201420.0×+1.2
2013Dec 31, 201318.8×+6.0
2012Dec 31, 201212.8×+3.8
2011Dec 30, 20119.0×+1.4
2010Dec 31, 20107.6×+1.1
2009Dec 31, 20096.6×–

More BioMarin Pharmaceutical figures

See a number that looks wrong?